Comparison of vasoactive intestinal peptide-mediated protein phosphorylation in human lymphoblasts and colonic epithelial cells.

O'Dorisio MS, Campolito LB

Molecular immunology1 Jun 1989Cited by 4 (Europe PMC)

PMID2770750DOI10.1016/0161-5890(89)90010-2PepBankPUB-02770750

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Mechanism
In human lymphoblastic (Molt 4b) and colon carcinoma (HT29) cell lines, VIP induced phosphorylation of a basic 38,000 mol. wt protein.
In plain wordsIn human lab-grown lymphoblast and colon cancer cells, VIP caused a 38,000 mol. wt protein to be phosphorylated.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePhosphorylation of 38,000 mol. wt protein
Study
humann: not reported in source
Molt 4b lymphoblastic and HT29 colon carcinoma cell lines
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Vasoactive intestinal peptide (VIP) induces phosphorylation of a basic 38,000 mol. wt protein in a human lymphoblastic cell line (Molt 4b) and a human colon carcinoma cell line (HT29).
Report a problemFND-0277075001
02LabIn vitro (cells)Activity measurement
In both Molt 4b and HT29 cells, VIP interacted with specific high affinity receptors to activate adenylate cyclase and cAMP-dependent protein kinase.
In plain wordsIn human lab-grown cells of two types, VIP bound to specific receptors and switched on adenylate cyclase and a protein kinase.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVIP receptor activation of adenylate cyclase and cAMP-dependent protein kinase
Study
humann: not reported in source
Molt 4b lymphoblastic and HT29 colon carcinoma cell lines
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
In both cell types, VIP interacts with specific high affinity receptors to activate adenylate cyclase and cAMP-dependent protein kinase.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal peptide (VIP) induces phosphorylation of a basic 38,000 mol. wt protein in a human lymphoblastic cell line (Molt 4b) and a human colon carcinoma cell line (HT29).
Report a problemFND-0277075002
03LabIn vitro (cells)Activity measurement
The two cell types appeared to express homologous VIP receptors with similar affinity and specificity, but colonic epithelial cells expressed a greater number of receptors.
In plain wordsIn human lab-grown cells, the VIP receptors in the two cell types were alike in affinity, but colon cells had more receptors.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
MixedVIP receptor affinity and number
Study
humann: not reported in source
Molt 4b lymphoblastic and HT29 colon carcinoma cell lines
Comparator
Molt 4b lymphoblasts versus HT29 colonic cells
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
The two cell types appear to express homologous receptors with similar affinity and specificity for VIP, but the colonic epithelial cells express a greater number of receptors.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal peptide (VIP) induces phosphorylation of a basic 38,000 mol. wt protein in a human lymphoblastic cell line (Molt 4b) and a human colon carcinoma cell line (HT29).
Report a problemFND-0277075003
04LabIn vitro (cells)Activity measurement
HT29 colonic cells showed a greater stimulation of adenylate cyclase in response to VIP than lymphoblasts.
In plain wordsIn human lab-grown cells, VIP switched on adenylate cyclase more strongly in colon cells than in lymphoblast cells.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP-stimulated adenylate cyclase activity
Study
humann: not reported in source
Molt 4b lymphoblastic and HT29 colon carcinoma cell lines
Comparator
Molt 4b lymphoblasts versus HT29 colonic cells
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
HT29 colonic cells also exhibit a greater stimulation of adenylate cyclase and a higher phosphorylation index for the 38,000 mol. wt protein in response to VIP.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal peptide (VIP) induces phosphorylation of a basic 38,000 mol. wt protein in a human lymphoblastic cell line (Molt 4b) and a human colon carcinoma cell line (HT29).
Report a problemFND-0277075004
05LabIn vitro (cells)Mechanism
HT29 colonic cells showed a higher phosphorylation index for the 38,000 mol. wt protein in response to VIP than lymphoblasts.
In plain wordsIn human lab-grown cells, VIP caused more protein phosphorylation in colon cells than in lymphoblast cells.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicablePhosphorylation index of 38,000 mol. wt protein in response to VIP
Study
humann: not reported in source
Molt 4b lymphoblastic and HT29 colon carcinoma cell lines
Comparator
Molt 4b lymphoblasts versus HT29 colonic cells
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
HT29 colonic cells also exhibit a greater stimulation of adenylate cyclase and a higher phosphorylation index for the 38,000 mol. wt protein in response to VIP
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal peptide (VIP) induces phosphorylation of a basic 38,000 mol. wt protein in a human lymphoblastic cell line (Molt 4b) and a human colon carcinoma cell line (HT29).
Report a problemFND-0277075005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.